New Cancer-Killing Virus Tested On Humans For The First Time

New Cancer-Killing Virus Tested On Humans For The First Time
SHARE

For the very first time, a human patient has received a new cancer-killing virus, with the goal of discovering new ways to combat cancer tumors in people’s bodies.

It’s an oncolytic virus, or CF33-hNIS (aka Vaxinia), a genetically altered virus that’s been engineered to infect and destroy cancer cells alone, leaving healthy cells unharmed.

As with CF33-hNIS, the altered pox virus enters cells and multiplies itself in order to spread. There are hundreds of new virus particles that are released when the infected cell bursts; these antigens stimulate the immune system to target neighboring cancer cells. However, no human trials of the medicine have been conducted thus far, despite previous studies showing that it can engage the immune response in this manner and target cancer cells.

The first human clinical trial

Just recently, the drug’s co-developers announced the start of the first human clinical study. The first step in uncovering that potential is to prove that CF33-hNIS is suitable for patients to take, and the first part of the study will concentrate on that 

Approximately 100 patients with severe solid tumors and a minimum of two previous lines of conventional therapy are scheduled to participate in the study. These participants will get modest dosages of the investigational therapy intravenously or by direct injection after they have been accepted into the study.

CF33-hNIS and pembrolizumab will be tested together if early results are positive and CF33-hNIS is found to be safe and well-tolerated.

HNIS, the protein that allows researchers to see and track viral replication and kill cancer cells with radioactive iodine, is present in the form of the virus now being tested in clinical trials.

However, before effectiveness can be proven, researchers must first evaluate how well patients manage the treatment, document the incidence and intensity of any side effects, and investigate how well volunteers cope when low dosages are elevated.

This experiment is scheduled to last two years and includes numerous clinical sites; thus, we won’t know the findings of secondary measures such as how well CF33-hNIS decreases tumors until the trial is complete.

Though we might be enthusiastic about the wide potential of this study, we should temper our hopes since impressive outcomes in pre-clinical tests do not guarantee the same success in following human patient research. If the medicine proves to be effective and well-tolerated, we may have a potent new weapon in our arsenal in the battle against cancer.


SHARE
Anna Daniels

Anna is an avid blogger with an educational background in medicine and mental health. She is a generalist with many other interests including nutrition, women's health, astronomy and photography. In her free time from work and writing, Anna enjoys nature walks, reading, and listening to jazz and classical music.

Post Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.